title: Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.
abstract: The aim of this study was to evaluate the role of serum CA125 levels and computerized tomography (CT) scans in predicting pathologic response of intraperitoneal chemotherapy in patients with ovarian cancer. We prospectively analyzed serum CA125 levels and abdominopelvic CT scans obtained after the completion of intraperitoneal chemotherapy in 52 patients with ovarian cancer and compared the results with subsequent laparotomic findings, which served as the gold standard for statistical analysis. Laparatomy revealed either microscopic or macroscopic residual disease in 20 patients, while 32 patients were completely tumor-free. CA125 levels correlated significantly with laparotomic findings (p=0.003, u=1405). Median CA125 values in patients with residual tumors and in tumor-free patients following intraperitoneal chemotherapy were 14.6 (1-775) and 7.2 (1-37) U/ml, respectively. Although CT-imaging and CA 125 levels had a high specificity (100% and 96.9%, respectively), they showed a low sensitivity rate (50% and 40%, respectively). Similarly, despite high positive predictive values (100% and 88.9%, respectively), the negative predictive values were 76.2% and 72.1%, respectively.
  
  
  CONCLUSIONS
  Although highly specific, CT scans and CA125 levels do not accurately indicate the presence of disease. Due to a high false-negative rate, a normal CT scan or a normal CA125 value is not sufficient to replace a laparotomy.
authors.affiliation: Institute of Oncology, University of Istanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Topuz
authors.forename: A
authors.initials: A
authors.lastname: Aydiner
authors.forename: P
authors.initials: P
authors.lastname: Saip
authors.forename: Y
authors.initials: Y
authors.lastname: Eralp
authors.forename: F
authors.initials: F
authors.lastname: Taş
authors.forename: Y
authors.initials: Y
authors.lastname: Salihoğlu
authors.forename: N
authors.initials: N
authors.lastname: Tenekeci
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D018283:Cystadenocarcinoma, Papillary / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007813:Laparotomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D018394:CA-125 Antigen